Public Release:  Identifying targets of autoantibodies

Journal of Clinical Investigation

Patients with the autoimmune disease systemic lupus erythematosus (SLE) produce autoantibodies that target can cause damage to multiple organ systems. The host factors that are targeted by autoantibodies produced by SLE patients are not fully understood.

In this issue of the Journal of Clinical Investigation, Jordan Price and colleagues at Stanford University developed a microarray to identify cytokines, chemokines, and other circulating proteins as potential targets of the autoantibodies produced by SLE patients. The authors identified several autoantibody targets, and determined that SLE patients with high levels of autoantibodies directed against the B cell activating factor (BAFF) had more severe SLE-associated symptoms.

In an accompanying commentary, Maureen Su of the University of North Carolina and Stephanie Sarantopoulos of Duke University discuss how identification of autoantibody targets produced by patients with autoimmune disorders will be informative for diagnosis and therapeutic strategy development.


TITLE: Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus

Stanford University, Stanford, CA, USA
Phone: 650.724.6743; Fax: ; E-mail:

View this article at:


TITLE: BAFF-ling autoantibodies

University of North Carolina, Chapel Hill, Chapel Hill, NC, USA
Phone: 919-597-0777; Fax: 919-843-7588; E-mail:

View this article at:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.